Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — Investor Presentation (July 2017)
24 slides from Emmaus Life Sciences's investor presentation, Jul 28, 2017
Slide 1: Predictive Medicine for Mental Health – Investor Presentation
PREDICTIVE MEDICINE FOR MENTAL HEALTH July2017 Investor Presentation NASDAQ: MYND
Slide 2: Disclaimer
Investor Presentation DISCLAIMER This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, comp
Slide 3: Investment Highlights
Investor Presentation • MYnd Analytics is a predictive analytics company that develops decision support tools to guide personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, and post - traumatic stress disorder (PTSD ) Our Business • MYnd’s Psychiatric Elect
Slide 4: Digital Health Care: Investments
Investor Presentation DIGITAL HEALTH CARE: INVESTMENTS MYND is in one of the hottest areas of AI/digital health care 4
Slide 5: Mental Health - Incidence & Cost
Investor Presentation 5 MENTAL HEALTH - INCIDENCE & COST • Globally, an estimated 3 0 0 million people suffer from depression and 60 million have Bipolar affective disorder . (1) • Anxiety disorders are the most common mental illness in the U.S. affecting 40 million adults. (2) • It is estimated tha
Slide 6: Mental Health & Substance Use Disorders U.S. Spending
Investor Presentation MENTAL HEALTH & SUBSTANCE USE DISORDERS (MHSUD) U.S. SPENDING • Mental disorders , including substance abuse, have the highest estimated annual health spending in the U . S. • In 2013, healthcare spending on mental disorders reached $201 Billion (1) 6 (1) “Mental Disorders Top
Slide 7: Impact of MHSUD on Common High Cost Medical Conditions
Investor Presentation Source: Melek S., Norris D., Paulus J.: Economic Impact of Integrated Medical - Behavioral Healthcare: Implications for Psychiatry. Prepared for APA; 2014, pp.1 - 39. 7 IMPACT OF MHSUD ON COMMON HIGH COST MEDICAL CONDITIONS IN 2012 Population % with Behavioral Health (BH) Diagn
Slide 8: Trial and Error Pharmacotherapy
Investor Presentation 8 Thomas R. Insel, MD 2009 - 2010 “ Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction of patients who ultimately respond, clinicians often must resort to trial and error before findin
Slide 9: Mental Health Medications Are Second Most Prescribed Therapeutic Class
Investor Presentation 9 MENTAL HEALTH MEDICATIONS ARE SECOND MOST PRESCRIBED THERAPEUTIC CLASS Dispensed Prescriptions (in millions) 2011 201 2 2013 2014 2015 US Marke t 4,01 4 4,15 5 4,2 36 4,32 5 4,36 8 Antihypertensives 649 691 701 705 70 6 Mental Health 495 511 523 537 54 7 Pain 47 2 48 4 4 81 4
Slide 10: Mental Health Market: Significant Unmet Need
Investor Presentation MENTAL HEALTH MARKET: SIGNIFICANT UNMET NEED Most get no formal treatment 10 Of all people living with mental disorders • 12% are treated by a psychiatrist • 20% are treated by a mental health physician • 40% are treated by a healthcare professional • 60% get no formal treatmen
Slide 11: Proprietary Outcomes Registry
Investor Presentation 11 PROPRIETARY OUTCOMES REGISTRY MYnd Clinical Registry 10,200 + Unique Patients 38,000+ Total Outcomes • Strong intellectual property protection with 22 issued patents and 1 patent pending • Technical know - how and proprietary algorithm developed and owned by MYnd • First mov
Slide 12: Growing Evidence
Investor Presentation 12 GROWING EVIDENCE “EEG recording and analysis is currently experiencing a renaissance in interest and in both range and depth of applications, particularly in the search for endo - phenotypes and biomarkers for etiologic factors, individual diagnosis, risk for disorder, and t
Slide 13: Trial and Error Pharmacotherapy
Investor Presentation 13 Thomas R. Insel , MD Former Director , Mental Health, Verily Life Sciences in April 2016 “Technology can make a difference for mental health care. Digital phenotyping, like what PEER does with EEG, or with wearables or smartphone technology, can capture precise, continuous,
Slide 14: Current Technologies Used to Guide Treatment
Investor Presentation 14 CURRENT TECHNOLOGIES USED TO GUIDE TREATMENT Category Clinical Practice Application Examples Functional imaging Identifies brain regions associated with cognitive impairments, hyper/hypoactivation ; no regulatory clearance for MH Amen Clinics Pharmacogenomic ( PGx ) testing
Slide 15: The Process
Investor Presentation An EEG test measures the patient’s unique brain patterns. The test is non - invasive , inexpensive, widely available and has a reimbursement code 2 1 Patient and Doctor agree PEER is needed (can be a Psychiatrist or Primary Care Physician) 3 Patient’s EEG is compared to PEER da
Slide 16: Interim Findings from the 4th Clinical Trial – Walter Reed PEER Trial
Investor Presentation 5 2 Peer Followed Standard of Care 144% 75% 75% 139% Depression SuicidalityGlobal Improvement PTS P e r c e n t 16 INTERIM FINDINGS FROM THE 4 TH CLINICAL TRIAL – WALTER REED PEER TRIAL Patients whose physicians followed PEER had more statistically significant improvement than
Slide 17: Commercialization Strategy
Investor Presentation 17 COMMERCIALIZATION STRATEGY Provider Direct Multi - practitioner provider groups seeking to provide value - based care and cutting edge objective measurement tools that are reimbursed Billing CPT Codes: 95816, 95957, 99090 VA/Military Where suicide rates are high and need for
Slide 18: Milestones Over Next Months
Investor Presentation 18 MILESTONES OVER NEXT 12 MONTHS 1 Establish paid pilot program(s) with managed care companies and health systems seeking to improve clinical outcomes and lower health care costs 2 Show pharmacoeconomic benefits when providers use the PEER report on - line tool 3 Penetrate VA
Slide 19: Additional Service Lines
Investor Presentation Problem Looming crisis in access to care: • Psychiatrist shortage • Waiting lists are high • 70% of mental health is treated by PCPs • Waste due to low attendance and adherence to treatment ( avg = 2 visits) Impact: • Over half of patients never seek treatment • Treatments them
Slide 20: Capitalization
Investor Presentation 20 CAPITALIZATION MYND Analytics Inc. Securities Issued Shares (As of July 19, 2017) Common Stock Issued and Outstanding 4 , 214 ,061 Total Shares of Common Stock Underlying Issued Options 3 53 , 546 Total Shares of Common Stock Underlying Issued Warrants (1) 4,220,872 Fully Di
Slide 21: Digital Health Care: 10 Largest Acquisitions in 2016
Investor Presentation Source: RockHealth, 2016 https:// rockhealth.com /reports/digital - health - exits - 2016 - ytd - 112 - digital - health - acquisitions - and - two - ipos/. DIGITAL HEALTH CARE In 2016 the 10 largest acquisitions brought in over $11B for shareholders 21 Target Acquired By Acqui
Slide 22: Experienced Leadership
Investor Presentation EXPERIENCED LEADERSHIP Board of Directors George C. Carpenter, IV – President & CEO • Over 25 years of experience in healthcare technology and business development • MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald – Chief Technology Offi
Slide 23: Key Investment Thesis
Investor Presentation KEY INVESTMENT THESIS • CLINICAL NEED: Mental disorders are the greatest cause of disability and number one reason why people miss work • MARKET OPPORTUNITY : $21 billion are spent annually on mental health medications making them the second most commonly prescribed therapeutic
Slide 24: Contact
Investor Presentation 24 CONTACT Robin L. Smith, MD, MBA, Chairman of the Board tel : 917 - 691 - 7409 email: robin@robinlsmith.com George C. Carpenter IV, President and Chief Executive Officer tel: 949 - 697 - 2161 email: gcarpenter@myndanalytics.com Don D’Ambrosio Chief Financial Officer tel : 949